A nomogram based on circulating CD8
CD8+ T cell
Immune function
Inflammatory markers
Nasopharyngeal carcinoma
Prognosis
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
received:
07
05
2024
accepted:
31
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
To explore the influence of circulating lymphocyte subsets, serum markers, clinical factors, and their impact on overall survival (OS) in locally advanced nasopharyngeal carcinoma (LA-NPC). Additionally, to construct a nomogram predicting OS for LA-NPC patients using independent prognostic factors. A total of 530 patients with LA-NPC were included in this study. In the training cohort, Cox regression analysis was utilized to identify independent prognostic factors, which were then integrated into the nomogram. The concordance index (C-index) was calculated for both training and validation cohorts. Schoenfeld residual analysis, calibration curves, and decision curve analysis (DCA) were employed to evaluate the nomogram. Kaplan-Meier methods was performed based on risk stratification using the nomogram. A total of 530 LA-NPC patients were included. Multivariate Cox regression analysis revealed that the circulating CD8 Circulating CD8
Identifiants
pubmed: 39138513
doi: 10.1186/s13014-024-02500-y
pii: 10.1186/s13014-024-02500-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Subventions
Organisme : the Key Research and Development Program Project of Guangxi Zhuang Autonomous Region
ID : GuikeAB23026020
Organisme : Natural Science Foundation of Guangxi Zhuang Autonomous Region
ID : 2023GXNSFBA026012
Informations de copyright
© 2024. The Author(s).
Références
Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet (London England). 2019;394(10192):64–80.
pubmed: 31178151
doi: 10.1016/S0140-6736(19)30956-0
Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1035–47.
Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295–305.
pubmed: 30613964
doi: 10.1002/ijc.32099
Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American joint committee on cancer/international union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncology Off J Am Soc Clin Oncol. 2005;23(27):6730–8.
doi: 10.1200/JCO.2005.16.790
Yang J, Liang ZG, Jiang YT, et al. Efficacy and safety of concurrent chemoradiotherapy combined with induction chemotherapy or adjuvant chemotherapy in patients with stage II-IVA nasopharyngeal carcinoma: a propensity score matching analysis and meta-analysis. Front Oncol. 2021;11:778836.
pubmed: 34926289
pmcid: 8678128
doi: 10.3389/fonc.2021.778836
Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncology Off J Am Soc Clin Oncol. 2015;33(29):3356–64.
doi: 10.1200/JCO.2015.60.9347
Su WH, Hildesheim A, Chang YS. Human leukocyte antigens and epstein-barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. Front Oncol. 2013;3:299.
pubmed: 24367763
pmcid: 3856645
doi: 10.3389/fonc.2013.00299
Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization of PD-L1 and PD-1 expression and CD8 + tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma. Am J Clin Oncol. 2018;41(12):1204–10.
pubmed: 29672367
doi: 10.1097/COC.0000000000000449
Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162–74.
pubmed: 34174189
doi: 10.1016/S1470-2045(21)00302-8
Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536–43.
pubmed: 34341578
doi: 10.1038/s41591-021-01444-0
Kato T, Noma K, Ohara T, et al. Cancer-Associated fibroblasts affect Intratumoral CD8(+) and FoxP3(+) T cells Via IL6 in the tumor microenvironment. Clin cancer Res Off J Am Association Cancer Res. 2018;24(19):4820–33.
doi: 10.1158/1078-0432.CCR-18-0205
Huang C, Ding J, Huang C, et al. Abnormal variation and prognostic significance of circulating immune cells in patients with nasopharyngeal carcinoma treated with chemoradiotherapy: a prospective cohort study. Translational cancer Res. 2023;12(12):3718–27.
doi: 10.21037/tcr-23-2024
Zhu J, Fang R, Pan Z, Qian X. Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma. BMC Cancer. 2022;22(1):716.
pubmed: 35768843
pmcid: 9241295
doi: 10.1186/s12885-022-09438-y
Xu T, Huang Z, Su B, et al. Prognostic significance of circulating CD19 + B lymphocytes in EBV-associated nasopharyngeal carcinoma. Med Oncol (Northwood Lond Engl). 2014;31(10):198.
doi: 10.1007/s12032-014-0198-y
Kumarasamy C, Tiwary V, Sunil K, et al. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: a detailed PRISMA compliant systematic review and meta-analysis. Cancers. 2021;13:16.
doi: 10.3390/cancers13164166
Zeng X, Liu G, Pan Y, Li Y. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–49.
pubmed: 32603520
pmcid: 7412424
doi: 10.1111/jcmm.15097
Gianni C, Palleschi M, Schepisi G, et al. Circulating inflammatory cells in patients with metastatic breast cancer: implications for treatment. Front Oncol. 2022;12:882896.
pubmed: 36003772
pmcid: 9393759
doi: 10.3389/fonc.2022.882896
Zhou JY, Chen T, Li W, Ye K, Wei ZB. Effect of pretreatment serum LDH and ALP levels on the prognosis of patients with nasopharyngeal carcinoma. Lin chuang er bi yan hou tou jing wai ke za zhi = J Clin Otorhinolaryngology Head Neck Surgery. 2017;31(14):1069–1073.
Lu ZJ, Liu LT, Sun XS, et al. Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2021;162:202–11.
doi: 10.1016/j.radonc.2021.03.035
Su K, Huang W, Li X, et al. Evaluation of Lactate Dehydrogenase and Alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocellular Carcinoma. 2023;10:69–79.
doi: 10.2147/JHC.S398632
Yang H, Wang K, Liang Z, et al. Prognostic role of pre-treatment serum albumin in patients with nasopharyngeal carcinoma: a meta-analysis and systematic review. Clin Otolaryngology Off J ENT-UK Official J Neth Soc Oto-Rhino-Laryngology Cervico-Facial Surg. 2020;45(2):167–76.
doi: 10.1111/coa.13454
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.
pubmed: 15308095
doi: 10.1016/j.immuni.2004.07.017
Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209–23.
pubmed: 34253904
doi: 10.1038/s41577-021-00574-3
Huff WX, Kwon JH, Henriquez M et al. The evolving role of CD8(+)CD28(-) immunosenescent T cells in cancer immunology. Int J Mol Sci 2019;20(11).
Xu X, Wei F, Xiao L, et al. High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy. J Translational Med. 2023;21(1):64.
doi: 10.1186/s12967-023-03912-2
Chen M, Jin F, Ma L. The detection and significance of T cells in nasopharyngeal carcinoma patients. J Cancer Res Ther. 2018;14(Supplement):S331–5.
pubmed: 29970685
doi: 10.4103/0973-1482.235350
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.
pubmed: 20303878
pmcid: 2866629
doi: 10.1016/j.cell.2010.01.025
Li Q, Yu L, Yang P, Hu Q. Prognostic value of inflammatory markers in nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. Cancer Manage Res. 2021;13:6799–810.
doi: 10.2147/CMAR.S311094
Zhang J, Feng W, Ye Z, et al. Prognostic significance of platelet-to-lymphocyte ratio in patients with nasopharyngeal carcinoma: a meta-analysis. Future Oncol (London England). 2020;16(5):117–27.
doi: 10.2217/fon-2019-0520
Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci. 2016;53(6):409–30.
pubmed: 27282765
doi: 10.1080/10408363.2016.1200008
Laursen I, Briand P, Lykkesfeldt AE. Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res. 1990;10(2a):343–51.
pubmed: 2346307
Schwartz MK. Lactic dehydrogenase. An old enzyme reborn as a cancer marker? Am J Clin Pathol. 1991;96(4):441–3.
pubmed: 1892120
doi: 10.1093/ajcp/96.4.441
Zhang Y, Xu T, Wang Y, et al. Prognostic role of Lactate Dehydrogenase expression in urologic cancers: a systematic review and Meta-analysis. Oncol Res Treat. 2016;39(10):592–604.
pubmed: 27710971
doi: 10.1159/000449138
Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol (Stockholm Sweden). 2015;54(7):961–70.
doi: 10.3109/0284186X.2015.1043026
Zhang M, Wei S, Su L, et al. Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population: a meta-analysis. Medicine. 2016;95(35):e4494.
pubmed: 27583859
pmcid: 5008543
doi: 10.1097/MD.0000000000004494
Ng WT, Chan SH, Lee AW, et al. Parapharyngeal extension of nasopharyngeal carcinoma: still a significant factor in era of modern radiotherapy? Int J Radiat Oncol Biol Phys. 2008;72(4):1082–9.
pubmed: 18410997
doi: 10.1016/j.ijrobp.2008.02.006
Xiao G, Cao Y, Qiu X, et al. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer. 2013;13:226.
pubmed: 23642234
pmcid: 3672024
doi: 10.1186/1471-2407-13-226
Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005;62(3):672–9.
pubmed: 15936544
doi: 10.1016/j.ijrobp.2004.11.002
Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61(4):1107–16.
pubmed: 15752890
doi: 10.1016/j.ijrobp.2004.07.702
Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80(3):661–8.
pubmed: 20643517
doi: 10.1016/j.ijrobp.2010.03.024
Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys. 2001;50(5):1181–9.
pubmed: 11483327
doi: 10.1016/S0360-3016(01)01537-1
Zhong L, Dong D, Fang X, et al. A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: a multicentre study. EBioMedicine. 2021;70:103522.
pubmed: 34391094
pmcid: 8365370
doi: 10.1016/j.ebiom.2021.103522
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–180.
pubmed: 25846097
pmcid: 4465353
doi: 10.1016/S1470-2045(14)71116-7